Table 1.
PD-L1 antibody clones and recommended algorithms to -identify PD-L1 immunopositivity determined in clinical trial settings.
| PD-L1 antibody Clones | UC | HSCC | BC |
|---|---|---|---|
| 22C3 | CPS ≥ 10 | CPS ≥ 1 | CPS ≥ 1 |
| SP142 | IC ≥ 5% | IC ≥ 5% | IC ≥ 1% |
| SP263 | TC ≥ 25% or IC ≥ 25% | TC ≥ 25% | NA |
UC: urothelial carcinoma, HSCC: head and neck squamous cell carcinoma, BC: breast carcinoma, NA: not available.